Bosto, Mass. – A major breakthrough in the treatment of amyotrophic lateral sclerosis, known as ALS, can potentially help stop the disease in its tracks in as much as half of the cases in the U.S., a Northeastern University scientist says. Jeffrey Agar, associate professor of chemistry and pharmaceutical sciences...
treatment News
San Diego, Calif. – Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant non-small cell lung cancer (NSCLC), according to research presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer. BAY 2927088 is...
Farmington, Conn. – Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of an investigational, once-a-day pill called brensocatib as a therapy for the chronic lung condition. The clinical trial findings are...
Brentuximab vedotin produces durable responses and prolongs progression-free survival (PFS), when compared with physician’s choice of therapy, in previously treated patients with CD30-expressing cutaneous T-cell lymphoma (CTCL), according to final results from the ALCANZA study published in Blood Advances. The phase 3 ALCANZA trial (ClinicalTrials.gov Identifier: NCT01578499) enrolled 131 patients with mycosis...
Brentuximab vedotin produces durable responses and prolongs progression-free survival (PFS), when compared with physician’s choice of therapy, in previously treated patients with CD30-expressing cutaneous T-cell lymphoma (CTCL), according to final results from the ALCANZA study published in Blood Advances. The phase 3 ALCANZA trial (ClinicalTrials.gov Identifier: NCT01578499) enrolled 131 patients with mycosis...
(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patient Treatment well-tolerated and patient remains on study with stable disease elsewhere Sustained clinical response supports Bria-OTS personalized, off-the-shelf immunotherapy approach in Phase 1/2a metastatic breast cancer study PHILADELPHIA,...
SEONGNAM, South Korea and NEWTON, Mass — Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced that the company has initiated the Phase 1/2 clinical trial evaluating the safety, tolerability, and antitumor activity of BBT-207 in non-small cell lung cancer (NSCLC)...
PALO ALTO, Calif. — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) for encaleret for the treatment of individuals living with autosomal dominant hypocalcemia type...
PALO ALTO, Calif. — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for acoramidis, an investigational drug for the treatment of ATTR-CM. The...
PALO ALTO, Calif. and BERLIN, Germany — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and Bayer today announced a partnership wherein BridgeBio grants Bayer an exclusive license to commercialize acoramidis for ATTR-CM in Europe. In exchange, BridgeBio will receive up to $310 million USD comprising of upfront and near-term milestone payments,...